CRSP vs NTLA
CRSP and NTLA side by side — valuation & fundamentals (public data).
Key statistics
| Metric | CRSPCRISPR THERAPEUTICS AG | NTLAINTELLIA THERAPEUTICS, INC. |
|---|---|---|
| Market cap | $4.85B | $1.63B |
| P/S | 1394.5x | 24.9x |
| Revenue growth (YoY) | -90.6% | 16.9% |
| Earnings growth (YoY) | -58.8% | 20.5% |
| EBIT margin | -18933.6% | -651.7% |
| ROE | -35.3% | -56.7% |
| ROIC | -32.5% | — |
| 1y total return | -21.1% | -4.7% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: CRSP vs NTLA
| Metric | CRSP | NTLA |
|---|---|---|
| End value | $35.5K | $9.2K |
| Total return | +254.8% | -7.5% |
| CAGR | +13.4% | -0.8% |
| Volatility | 63.9% | 78.4% |
| Sharpe | 0.45 | 0.33 |
| Sortino | 0.69 | 0.49 |
| Max drawdown | -85.1% | -96.5% |
Based on 2523 common trading days, 2016-10-19 → 2026-11-02 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)